Abemaciclib: A New Standard of Care for High-risk EBC Patients

Dear Dr. Renukaprasad A R, Can adding abemaciclib to endocrine therapy (ET) provide additional benefits in patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC)? For answers to this and other pressing questions, join us for an interactive webinar on 31st March 2023, from 8:00-9:30 PM, where renowned oncologists Dr. Olga Oikonomidou (UK), Dr. Sandeep Goyle (India), Dr. Tejinder Singh (India), and Dr. Shivam Shingla (India) will discuss the clinical efficacy and benefits of abemaciclib in HR+/HER2-, node-positive, high-risk EBC patients. Session highlights: Benefits of abemaciclib beyond treatment completion in the adjuvant setting 4-year updates - Dr. Olga Oikonomidou Updates from ESMO 2022: Monarch 3 overall survival interim analysis - Dr. Tejinder Singh Case by case: Applying MonarchE data into clinical practice - Dr. Olga Oikonomidou Q&A with experts - Moderated by Dr. Sandeep Goyle Save the Date Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*